Sunday, February 23, 2014

Alaska Legislator Introduces Compounding Legislation

HB 319, Drug/Device Distributors: Compounded RX;
quoted from here

Virginia law does not allow using compounded drugs for execution even if they were available-bill introduced to allow execution by electrocution

During the week:
 
Execution by electrocution bills -- (HB1052 Miller and (SB607) Carrico --  are examples of identical bills that meander successfully through several committee hearings and floor debates but receive opposite results in the opposite body.  With new information and continuing confusion about lethal drug availability SB607 was defeated in the Senate Courts of Justice Committee. HB1502, however, survived the House committees and the House Floor 64-32 sending it to the Senate for action where it was defeated in a committee and never went to the Senate floor for a vote. Currently, Virginia law does not allow using compounded drugs for execution even if they were available. Further confusion occurred with the report that the Department of Corrections has obtained a substitute drug.
quoted from here

Australia's Queensland Health Confirms compounded drugs were contaminated

  • Australia’s Queensland Health says that a fungal contamination occurred in a bad batch of chemotherapy drugs used to treat 17 Queensland cancer patients, ABC reported.
  • Queensland Health says the patients were in public and private hospitals across the state and have not suffered any adverse effects to date, but are being closely monitored by their clinicians.
  • The Therapeutic Goods Administration (TGA) issued a product recall notice for compounded drugs manufactured by Fresenius Kabi Australia Proprietary Limited two weeks ago.
  • The TGA says a risk assessment by Fresenius Kabi found there is a potential risk for patients as the sterility of product may have been compromised.
  • All affected stocks of the suspect drug have now been recalled.
  • To read more NewsPoints articles, click here.

    American Health Lawyers Association: Update Federal Legislative Response to the Controversy Over Compounding

    NM Racing Commission Reverses Decision, Will Allow Closely-Monitored Clenbuterol Use
    The New Mexico Racing Commission has decided to end its current ban on the use of clenbuterol, and will now allow it to be given in closely-monitored, “miniscule” amounts.
     
    quoted from here

    Saturday, February 22, 2014

    Bulk Drug Substances That May Be Used to Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Request for Nominations--41 comments received so far

    source found here

    Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Request for Nominations-12 comments submitted so far--4 available for public to view

    Comments

    View All (4)


    Public Hearing Scheduled for February 25, 2014 on compounding legislation in Connecticut

    An Act Concerning the Pharmacy Practice Act and Counterfeit Drugs bill which is HB 5262, can be reviewed by clicking here. A group of Connecticut compounding pharmacists met at CPA offices this week to further discuss the proposed and submit comments to the Department of Consumer Protection. A public hearing on this is scheduled for this Tuesday, February 25, 2014

    quoted from here

    Upton Touts Committee’s Landmark Drug Quality and Security Law During Visit to Michigan Drug Manufacturer February 21, 2014 -

    Upton: “Across the nation, Americans going to the doctor’s office or pharmacy will now have the confidence that their drugs are safe.” 
    House Energy and Commerce Committee Chairman Fred Upton (R-MI) visited Allegan, Michigan, drug manufacturer Perrigo Company this week to celebrate the enactment of the H.R. 3204, the Drug Quality and Security Act. The Drug Quality and Security Act was the product of a bipartisan, bicameral breakthrough led by Chairman Upton following the committee’s yearlong investigation of the fungal meningitis outbreak. The bill protects traditional pharmacies and clarifies laws related to human drug compounding while also strengthening the prescription drug supply chain in order to defend American families against counterfeit drugs and to protect jobs. Perrigo is one of the world’s largest generic drug manufacturers and employs approximately 3,500 people in West Michigan. As Upton explained during his visit to Perrigo, “Not only does it help employers with jobs created here - it also helps consumers at the end because they know the drugs they take are much safer.”
    - See more at: http://energycommerce.house.gov/icymi/upton-touts-committee%E2%80%99s-landmark-drug-quality-and-security-law-during-visit-michigan-drug#sthash.rGoaQaaQ.dpuf

    Very Scary--And Shows different Concentrations used by compounding pharmacies in medications for kids

    ANN ARBOR: U-M leads state effort to create new standards for kids’ medicine, reduce medication errors - Ann Arbor Journal - Heritage Newspapers

    Bill introduced into Colorado to allow prescription drug outlet to distribute compounded drugs for office use to hospitals

    SB14-095 Pharmacies Compounding Drugs For Hospitals 
    Amendments:
    Date Introduced:2014-01-22
    Status:02/11/2014 Introduced In House - Assigned to Health, Insurance, & Environment
    Summary:Under current law, a prescription drug outlet may only distribute compounded drugs for office use to practitioners who are authorized to prescribe drugs. The bill allows a prescription drug outlet to also distribute compounded drugs to a hospital located in Colorado.
    Calendar Notification: Tuesday, March 4 2014
    Health, Insurance & Environment
    Upon Adjournment Room 0107
    (1) in house calendar.
    Sponsors:KEFALAS / MCCANN

    What Do the New Sterile Compounding Pharmacy Regulations Mean to You?

    What Do the New Sterile Compounding Pharmacy Regulations Mean to You?

    Friday, February 21, 2014

    4th Circuit Court of Appeals Issues Decision holding that because compliance with cGMPs is not required for payment by Medicare and Medicaid, the defendant had not falsely stated compliance to the government as contemplated by the FCA.

    FDA to enhance drug import security

    read here

    FDA to boost India staff overseeing drug imports

    By MATTHEW PERRONE, Associated Press
    Feb. 21, 2014 1:22PM PST
    WASHINGTON (AP) — The head of the Food and Drug Administration said Friday that her agency will add more inspectors in India to better monitor drugs from the country's burgeoning pharmaceutical industry, even as her agency also seeks closer cooperation from Indian regulators.
    FDA Commissioner Margaret Hamburg said the FDA will expand to 19 staffers in India from its current 12, as the U.S. tries to assure the safety of medications from companies like Ranbaxy Laboratories Ltd. and Wockhardt Ltd. Hamburg spoke with reporters following an eight-day trip to the Southeast Asian nation, where she met with Indian health regulators and drug industry executives.
    With sales of more than $26 billion, India's burgeoning drug sector has grown into the U.S.'s second-largest supplier of prescription and over-the-counter medications, behind only Canada.
    But that growth has come with increased scrutiny. And in recent years the FDA has issued a stream of warnings letters and import bans to some of India's largest drugmakers over manufacturing and quality control problems.
    The capstone of Hamburg's visit was a "statement of intent" agreement between the U.S. and India, in which both parties pledged to cooperate on safety and quality inspections. Under the non-binding agreement, Indian inspectors will be able to shadow their FDA counterparts as they inspect factories in India. The document is supposed to cover a 5-year preliminary period, though it's unclear how or when it might lead to more formal requirements.
    continue to read here

    FDA wants to revamp its nonprescription drug regulations

     

     By Matthew Perrone               

    The Food and Drug Administration is seeking to revamp its system for regulating hundreds of over-the-counter drugs, saying the decades-old process is not flexible enough to keep pace with modern medical developments.
    In a federal posting Friday, the agency announced a two-day meeting next month to discuss overhauling the system known as the over-the-counter monograph.
    continue to read here
     

    Job Opening: Compounding Pharmacy Business Manager (Bellevue)

    Compounding Pharmacy Business Manager (Bellevue)
    Paramount Pharmacy is looking for an outstanding full-time (100% FTE) Compounding Pharmacy Business Manager with pharmacy billing experience to join our Pharmacy team. This position requires Pharmacy Technician licensure and is responsible for assisting Paramount Pharmacy by performing non-professional/technical tasks related to delivery of pharmaceutical services.

    These functions may include:
    •Verification of Benefits with Patients prior to filling prescription
    •Customer Service
    •Pharmacy Billing (finalizing submission)
    • Revenue Cycle Management
    •Adheres to Paramount Pharmacy Services policies and procedures
    • Performs related duties as required
    •The successful candidate will build and manage a customer service team of pharmacy technicians

    Paramount Pharmacy offers a comfortable work environment, excellent benefits, a competitive salary. This position provides opportunities to work in a fast-paced, challenging, diverse and rewarding environment.

    Requirements:
    •Compound Pharmacy Billing experience as a Pharmacy Technician or equivalent education/experience.
    •Must pass background check and drug test

    Legal Requirement:
    •Pharmacy Technician licensure with State of Washington (Dept. of Health)
    •Desired: More than 1 year of Compound Pharmacy Technician experience or significant customer service experience preferred.
    quoted from here

    Demand for compounded drugs grows as awareness increases - Dothan Eagle: News

    Demand for compounded drugs grows as awareness increases - Dothan Eagle: News

    Ninth Question of the Day February 21, 2014 Should patients be able to demand copies of sterility/potency test when they pick up their compounded prescription from their pharmacy?


    Eighth Question of the Day February 21, 2014 Should a compounding ethics course be mandatory in all pharmacy schools?


    Seventh Question of the Day February 21, 2014 Should any pharmacy and medical establishment doing a high volume of pain compounds be audited and investigated?


    Sixth Question of the Day February 21, 2014 Will compounding pharmacies who plan only to do patient-specific compounds be able to stay in business doing just patient-specific compounds?


    New Mexico passes bill to crack down on horse racing cheaters; Governor Will Sign Bill Into Law Within Next Three Weeks

    By Rob Nikolewski on February 21, 2014
    Print This Post Print This Post

    By Rob Nikolewski │ New Mexico Watchdog
    SANTA FE  – After developing a reputation as a haven for cheaters, New Mexico is trying to clean up its act when it comes to horse racing.
    In the just-completed 30-day legislative session, lawmakers in Santa Fe, lawmakers passed a bill aimed at cracking down on trainers and owners who dope their horses with performance-enhancing drugs.
    “I say that horse racing is the sport of kings and we don’t want it to be the sport of cheaters,” said Sen. Mary Kay Papen, D-Las Cruces, of Senate Bill 116, which passed both chambers of the New Mexico legislature unanimously. Gov. Susana Martinez has indicated she will sign the bill into law in the within the next three weeks.
    - See more at: http://newmexico.watchdog.org/20577/new-mexico-passes-bill-to-crack-down-on-horse-racing-cheaters/#sthash.Z4rAjKJ6.dpuf

    Fifth Question of the Day February 21, 2014 What legal warranties are provided with compounded medications?


    Fourth Question of the Day February 21, 2014 Do most consumers realize that if a compounding pharmacy says its compounds "passed" a sterility test does not guarantee that every unit in that batch is sterile?


    Third Question of the Day February 21, 2014 Should there be tort liability on the part of pharmacies, pharmacists, hospitals, doctors, etc. for the failure to warn or notify patients that compounded drugs have not been clinically studied and or not FDA approved?


    Second Question of the Day February 21, 2014 Manufactured drugs go through pre, in and post processes of quality and performance testing ( and even at that some still end up causing great harm to patients); compounded drugs go through little or in most case none of these type studies and testing. From a legal liability stand point, this theory has not been devloped in the court system. Should it be?

     

    Question of the Day February 21, 2014 What are the risk of taking HCG as a diet add in a compounded nasal spray?

    This pharmacy, Benevere, offers it. see here  How many other compounding pharmacies are offering it?

    Hospital Pharmacist To Work On Goal of Providing Compounds

    February 20th, 2014
    Proteau-RositaDr. Rosita Rodriguez Proteau is the new pharmacist at the OSU Veterinary Teaching Hospital. She received her pharmacy degree and Ph.D. degree in Pharmacology/Toxicology from the University of Texas at Austin and has worked in the OSU College of Pharmacy as an Associate Professor for the past 17 years.
    Dr. Proteau has taught pharmaceutics and pharmacokinetics in the College of Pharmacy’s professional program and toxicokinetics in the Department of Environmental and Molecular Toxicology.
    Over the years, Dr. Proteau has collaborated with many investigators on campus in various pharmacokinetic studies in a variety of species.  Here at CVM, she will assist Dr. Brian Bowers in setting up a 797 sterile drug room such that the Veterinary Hospital Pharmacy can expand the options for compounded drugs.
    Dr. Proteau will continue to teach in the College of Pharmacy by offering Advanced Compounding and Veterinary Pharmacy electives to the Pharm.D. students.  In her spare time, she enjoys spending time on the coast and traveling.
    quoted from here

    Court filing: Missouri finds new pentobarbital supplier ahead of next week's planned execution

    read here

    Critical Intravenous Solution Shortages

    Critical Intravenous Solution Shortages

    The View From the FDA

    Laurie Scudder, DNP, NP, Valerie Jensen, RPh
    Disclosures February 20, 2014
    read here

    MUST WATCH! Dingell Questions FDA Commissioner Hamburg on Compounding --YouTube Video on Compounding Explaining Needs and Risks

    watch here

    Abbott Laboratories Recall of Veterinary Meloxicam

    Veterinary OroCAM is supplied in three glass vial sizes containing 6 mL, 11 mL and 33 mL of meloxicam. Each vial has a different metered dose pump delivering a dose of 0.25 mg, 0.50 mg, or 1.075 mg, per spray, respectively. Manufactured for Abbott Laboratories; North Chicago, IL 60064 USA; Product of Spain *** US PRODUCTS *** 1) 6 mL Vials. List Number 04943-04-01. Lot Codes and Expiration Dates: EMFG, 11/2014; FBDN, 02/2015; FEBU-3, 05/2015, FEBU-1, 05/2015. 2) 11 mL Vials. List Number 04943-04-02. Lot Codes and Expiration Dates: EMFF, 11/2014; FEBU-2, 05/2015. 3) 13 mL Vials. List Number 04943-04-03. Lot Codes and Expiration Dates: EMFG-1, 11/2014; EMGL, 11/2014; EMGM, 11/2014, EMGN, 11/2014. *** FOREIGN PRODUCTS *** 4) 6 mL Vials. List Number 04943-90-01. Lot Codes and Expiration Dates: EDEG-2, 05-2014; EKFE, 9-2014. 5) 6 mL Vials. List Number 04943-27-01. Lot Codes and Expiration Dates: EDEG, 05-2014. 6) 6 mL Vials. List Number 04943-03-01. Lot Codes and Expiration Dates: 33008XN, 10-2015.; 33004XN, 10-2015. 7) 11 mL vials. List Number 04943-90-02. Lot Codes and Expiration Dates: EDEG-3, 05 -2014; EFKE-1, 09-2014. 8) 11 mL Vials. List Number 04943-27-02. Lot Codes and Expiration Dates: EDGE-1, 05-2014. 9) 33 mL Vials. List Number 04943-27-03. Lot Codes and Expiration Dates: EDEH, 05-2014; EDEF, 04-2014; EHGM, 08-2014. 10) 33 mL Vials. List Number 04943-90-03. Lot Codes and Expiration Dates: EFFW, 06-2014; EHEK, 09-2014. Class II Some particles were observed in a limited number of OroCAM units. The particles if present could clog the pump mechanism and could also potentially result in under-administration. Abbott Laboratories


     
    quoted from here

    Thursday, February 20, 2014

    Enforcement Report - Week of February 19, 2014

    Enforcement Report - Week of February 19, 2014

    Reminder: Pharmacy Compounding: An Update from The Joint Commission, the Food and Drug Administration (FDA), and the American Society of Health-System Pharmacists (ASHP)

     

    Thursday, February 27, 2014 - 12:00 PM - 01:00 PM (CT)
    Short Description:
    The Joint Commission’s requirements for the compounding of human drugs, and tools organizations can use to assure the safety of compounded products.
    Attendance is limited to 1,000 people.  A replay will be posted on The Joint Commission website after the webinar and the link to the replay will be published in Joint Commission Online.

    Queensland Health confirms 17 cancer patients given contaminated drugs in hospital

    The health of 17 cancer patients in hospitals in Queensland has been put at serious risk by a contaminated batch of drugs, authorities say.
    Queensland Health says the patients were in public and private hospitals across the state.
    Department spokeswoman Dr Jeannette Young says the patients have been receiving chemotherapy and the contaminated drugs could be a major risk to their weakened immune systems.
    She says after receiving the advice, doctors were immediately asked to check on the wellbeing of those patients.
    Dr Young says the patients who took the drugs have not suffered any adverse effects to date, but are being closely monitored by their clinicians.
    The Therapeutic Goods Administration (TGA) issued a product recall notice for compounded drugs manufactured by Fresenius Kabi Australia Proprietary Limited last Thursday.
    The TGA says a risk assessment by Fresenius Kabi found there is a potential risk for patients as the sterility of product may have been compromised.
    Fresenius Kabi has not received any reports of adverse events associated with this failure.
    She says affected stocks of the suspect drug have now been recalled.
    quoted from here

    Cancer patients given contaminated compounded drugs in Australia: TGA advised compounded drugs manufactured by Fresenius Kabi Australia had been recalled, after the company concluded "there is a potential risk for patients as the sterility of product may have been compromised".

    Cancer patients given contaminated drugs

    read here